A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia

A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia
Recruiting
18 years - 45 years
All
Phase 1
30 participants needed
1 Location

Brief description of study

The purpose of this research is to test an experimental drug CVL-562 as a possible treatment for early-course schizophrenia, schizoaffective disorder or related psychotic disorder.

This study will test whether CVL-562 can help thinking and memory in people with schizophrenia.

Detailed description of study

The study involves 7 in-person visits, including an initial intake visit, 5 scan visits, and 1 follow up visit, as well as a brief phone check in 1 month after completion of the study. An investigational medication is taken prior to the scan on each of the 5 scan visits. In addition to medical assessments, subjects will participate in clinical interviews, cognitive assessments, and MRIs. Total compensation is up to $2,910.
    

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: schizophrenia,schizoaffective disorder,related psychotic disorders,schizophreniform disorder,psychosis
  • Age: 18 years - 45 years
  • Gender: All

To be eligible, study participants must meet DSM-5 criteria for a primary non-affective psychotic disorder (schizophrenia, schizoaffective, or schizophreniform) with onset of psychosis within the past 10 years. Psychiatric symptoms and treatment must be stable (no active/remarkable SI/HI, no anticipated need to change medications during study).  Patients must not have had an active moderate/severe substance use disorder (except nicotine).  Patients may be unmedicated, but only certain antipsychotics are allowed (olanzapine, clozapine, ziprasidone or asenapine are exclusionary), and certain other psychoactive medications are not allowed (stimulants or other current pharmacotherapy for ADHD, medical cannabis, anticonvulsants except when used as mood stabilizers).

Updated on 04 Aug 2024. Study ID: 842909

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center